Russian historical epic Viking to be released in Italy, UKSociety & Culture March 30, 2:11
Putin visits ice cave during Arctic tourSociety & Culture March 30, 0:02
West’s reaction to Russian protests part of long-planned campaign - diplomatRussian Politics & Diplomacy March 29, 23:56
Putin orders Defense Ministry and FSB to ensure protection of Russia’s interests in ArcticMilitary & Defense March 29, 21:46
Kiev aware of few chances to win in debt lawsuit case — envoyBusiness & Economy March 29, 20:52
Russian top diplomat dismisses claims about human rights violations in Crimea as liesRussian Politics & Diplomacy March 29, 20:23
Moscow suspects Jabhat al-Nusra could be used to topple AssadRussian Politics & Diplomacy March 29, 19:58
Lavrov reiterates there are no facts substantiating Iran’s links to terroristsRussian Politics & Diplomacy March 29, 19:40
Russia to upgrade helicopter protection system based on Syrian experienceMilitary & Defense March 29, 19:00
SAN FRANCISCO, March 2, 2016 /PRNewswire/. Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued a patent by the Federal Service for Intellectual Property (ROSPATENT), Ministry of Economic Development of the Russian Federation.
The ROSPATENT allowance covers a transgenic mouse with an engineered endogenous immunoglobulin locus deleted of its variable region gene segments and instead containing arrays of chimeric immunoglobulin gene segments. The chimeric gene segments consist of human immunoglobulin coding sequences and non-coding sequences based on the mouse immunoglobulin variable region locus. They thus confer the capacity to express antibody chains with human variable regions. The patent also covers the methods for generating the mouse.
"We are pleased with the addition of the Russian patent to our patent portfolio," commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This addition further strengthens TRIANNI's position in monoclonal antibody discovery platform."
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Zishan Haroon, MD, PhD
Chief Business Officer
Director of Marketing